Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 Versus T-DM1 in HER2-Positive Primary Breast Cancer With Residual Invasive Disease
NCT06126640Phase 3Active, not recruiting
- Sponsor
- Hengrui
- Start
- Nov 2023
- Primary completion
- Apr 2030
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab rezetecan in breast cancer, sponsored by Hengrui. Started Nov 2023; status: active, not recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06126640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06126640.